Zhang Yu, Yang Shan-Shan, Zhang Ni-Ni, Huang Gui-Lin
Hospital/School of Stomatology, Zunyi Medical University, 143 Dalian Road, Huichuan District, Zunyi City, Guizhou Province, 563006, China.
BMC Oral Health. 2025 Jul 5;25(1):1120. doi: 10.1186/s12903-025-06484-3.
The success of dental implant restoration is significantly influenced by the volume and density of alveolar bone in the surgical area. Maxillary sinus floor elevation (MSFE) surgery is a reliable method to increase residual bone height (RBH) before implantation. This study aimed to evaluate the impact of platelet-derived bone enhancers, namely platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and platelet-rich growth factor (PRGF), when used as adjuncts to deproteinized bovine bone matrix (DBBM) in MSFE on bone neoformation, implant stability, and implant survival.
A systematic review and meta-analysis were conducted following the PRISMA guideline. Electronic databases, including PubMed, Embase, CENTRAL, Web of Science, Scopus, and Google Scholar, were searched up to February 2025. Randomized controlled trials (RCTs), and case-control studies assessing the effect of PRP/PRF/PRGF as an adjuvant to DBBM in MSFE were included. Mean difference (MD) or risk ratio (RR) was selected as the effect size to perform the meta analysis.
Sixteen studies met the inclusion criteria, involving 372 patients and 455 surgical procedures. The meta-analysis revealed a significant enhancement of bone neoformation (MD = 5.92, 95%CI: 2.17 ~ 9.67, p = 0.002) and reduced residual graft volume (MD = -1.93, 95%CI: -2.25 ~ -1.61, p < 0.001) when PRP/PRF/PRGF was added to DBBM. However, there was no significant difference in graft resorption rate, percentage of fibrous tissue, immediate implant stability, and implant survival rate, between the two groups. Subgroup analyses showed that PRF subgroup, and subgroups with 4 m or 6 m healing intervals and with DBBM particles of 0.25-1 mm are related to significantly enhanced bone neoformation; all subgroups except for the PRP subgroup are related to significantly decreased residual graft.
The addition of PRF or PRGF to DBBM in the first stage of MSFE significantly enhances new bone formation and reduces residual graft volume, providing a more reliable alveolar bone matrix for subsequent implant placement. No evidence support the application of PRP as an effective enhancer to DBBM in MSFE procedure. In addition, PRP/PRF/PRGF does not significantly affect the immediate stability or survival of implants in the second stage.
牙种植修复的成功受到手术区域牙槽骨体积和密度的显著影响。上颌窦底提升(MSFE)手术是一种在种植前增加剩余骨高度(RBH)的可靠方法。本研究旨在评估富含血小板的血浆(PRP)、富含血小板的纤维蛋白(PRF)和富含血小板的生长因子(PRGF)这三种血小板衍生骨增强剂作为脱蛋白牛骨基质(DBBM)在MSFE中的辅助剂对骨新形成、种植体稳定性和种植体存活率的影响。
按照PRISMA指南进行系统评价和荟萃分析。检索了包括PubMed、Embase、CENTRAL、Web of Science、Scopus和Google Scholar在内的电子数据库,检索截止至2025年2月。纳入评估PRP/PRF/PRGF作为DBBM在MSFE中的辅助剂效果的随机对照试验(RCT)和病例对照研究。选择平均差(MD)或风险比(RR)作为效应量进行荟萃分析。
16项研究符合纳入标准,涉及372例患者和455例手术。荟萃分析显示,当PRP/PRF/PRGF添加到DBBM中时,骨新形成显著增强(MD = 5.92,95%CI:2.17 ~ 9.67,p = 0.002),剩余移植体积减少(MD = -1.93,95%CI:-2.25 ~ -1.61,p < 0.001)。然而,两组之间在移植吸收速率、纤维组织百分比、即刻种植体稳定性和种植体存活率方面没有显著差异。亚组分析表明,PRF亚组,以及愈合间隔为4个月或6个月且DBBM颗粒为0.25 - 1毫米的亚组与骨新形成显著增强有关;除PRP亚组外的所有亚组均与剩余移植显著减少有关。
在MSFE第一阶段将PRF或PRGF添加到DBBM中可显著增强新骨形成并减少剩余移植体积,为后续种植体植入提供更可靠的牙槽骨基质。没有证据支持在MSFE手术中应用PRP作为DBBM的有效增强剂。此外,PRP/PRF/PRGF对第二阶段种植体的即刻稳定性或存活率没有显著影响。